Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai MedicilonSHSE:688202 -1.69%64 Days Inventory is 64.43 as of Jun. 2026, which is 139% above its 10-year median of 26.97. GuruFocus rates SHSE:688202 with a GF Score™ of 64/100 and a GF Value™ of ¥50.24 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 642 Biotechnology companies, Shanghai Medicilon ranks better than 88.47% on this metric.
The historical rank and industry rank for Shanghai Medicilon's Days Inventory or its related term are showing as below:
SHSE:688202'
s Days Inventory Range Over the Past 10 Years
Min: 12.83 Med: 26.97 Max: 59.02
Current: 44.57
During the past 12 years, Shanghai Medicilon's highest Days Inventory was 59.02. The lowest was 12.83. And the median was 26.97.
SHSE:688202's Days Inventory is ranked better than 88.47% of 642
companies
in the Biotechnology industry
Industry Median: 184.19
vs SHSE:688202: 44.57
Shanghai Medicilon's Days Inventory
increased
from Jun. 2025 (33.31) to Jun. 2026 (64.43).
It might indicate that Shanghai Medicilon's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shanghai Medicilon's Inventory Turnover for the
three
months ended in Jun. 2026 was 1.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shanghai Medicilon's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.45.
Shanghai Medicilon (SHSE:688202) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Shanghai Medicilon's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shanghai Medicilon's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Shanghai Medicilon Days Inventory Related Terms
Shanghai Medicilon Days Inventory Historical Data
* Premium members only.
The historical data trend for Shanghai Medicilon's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688202 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Shanghai Medicilon's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Medicilon Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Days Inventory distribution charts can be found below:
* The bar in red indicates where Shanghai Medicilon's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Medicilon (SHSE:688202) has a Days Inventory of 64.43 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shanghai Medicilon and its competitors. This is 139% above median its historical median of 26.97. Over the past decade, Shanghai Medicilon's Days Inventory has ranged from 12.83 to 59.02. According to the industry distribution chart, Shanghai Medicilon ranks #74 out of 642 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Shanghai Medicilon's Days Inventory too high?
Shanghai Medicilon's current Days Inventory of 64.43 is 139% above median its 10-year median of 26.97. Over the past 10 years, this metric has ranged from a low of 12.83 to a high of 59.02. The Biotechnology industry median Days Inventory is 184.19. Shanghai Medicilon's value of 64.43 is 65% below this industry median. Based on the distribution chart, Shanghai Medicilon ranks #74 out of 642 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Medicilon has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #74 out of 642 companies for Days Inventory. This places Shanghai Medicilon in the top 12% of its industry — outperforming the majority of peers. The industry median Days Inventory is 184.19. Shanghai Medicilon's value of 64.43 is 65% below this benchmark. Historically, Shanghai Medicilon's own Days Inventory has ranged from 12.83 to 59.02 over the past decade. While the company's 10-year median is 26.97 vs. the industry median of 184.19, Shanghai Medicilon has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.19, based on 642 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Medicilon's current Days Inventory of 64.43 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shanghai Medicilon and its competitors. For the Biotechnology industry, the median Days Inventory is 184.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Medicilon's current Days Inventory is 64.43, which is 139% above median its own 10-year median of 26.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥50.24, compared to a current price of ¥93.24 — trading 85.6% above its estimated fair value. The current Days Inventory is 64.43, which is 139% above median its 10-year median of 26.97 and 65% below the Biotechnology industry median of 184.19. Shanghai Medicilon's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Days Inventory is 64.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued.
The current stock price of ¥93.24 is trading 85.6% above its estimated GF Value™ of ¥50.24.
GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.
Key valuation signals for SHSE:688202:
Days Inventory: 64.43 (139% above median its 10-year median of 26.97)
GF Value™: ¥50.24 vs. price of ¥93.24 (85.6% above fair value)
Industry Position: 65% below the Biotechnology median (#74 of 642)
No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
64GF Score
Get the complete analysis for SHSE:688202
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688202 has been successfully added to your 
